• LAST PRICE
    5.6500
  • TODAY'S CHANGE (%)
    Trending Down-0.2500 (-4.2373%)
  • Bid / Lots
    5.5500/ 4
  • Ask / Lots
    5.7900/ 1
  • Open / Previous Close
    5.7600 / 5.9000
  • Day Range
    Low 5.6500
    High 5.9900
  • 52 Week Range
    Low 4.8570
    High 24.5400
  • Volume
    4,324
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 5.9
TimeVolumeTHRX
09:32 ET3625.76
09:45 ET1005.99
09:48 ET1005.99
09:56 ET1005.99
10:01 ET4355.8477
10:19 ET1005.835
10:21 ET17825.65
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTHRX
Theseus Pharmaceuticals Inc
223.8M
-5.8x
---
United StatesSTSA
Satsuma Pharmaceuticals Inc
221.4M
-2.8x
---
United StatesCMPX
Compass Therapeutics Inc.
192.4M
-6.8x
---
United StatesLIAN
LianBio
202.6M
-2.1x
---
United StatesOMER
Omeros Corp
210.1M
-1.2x
---
United StatesNAUT
Nautilus Biotechnology Inc
244.3M
-4.3x
---
As of 2022-10-05

Company Information

Theseus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The Company is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The Company's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.

Contact Information

Headquarters
314 Main Street, Suite 04-200CAMBRIDGE, MA, United States 02142
Phone
857-400-9491
Fax
302-655-5049

Executives

Executive Chairman of the Board, Co-Founder
Iain Dukes
President, Chief Executive Officer, Director
Timothy Clackson
Co-Founder, Chief Technical Officer
David Dalgarno
Co-Founder, Chief Scientific Officer
Victor Rivera
Chief Financial Officer
Bradford Dahms

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$223.8M
Revenue (TTM)
$0.00
Shares Outstanding
38.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.98
Book Value
$6.37
P/E Ratio
-5.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.